GLP1R and obesity disorder: One of the recent studies investigating the role of GLP-1 RA in HF was the STEP-HFpEF Trial in which 529 HFpEF patients with obesity were randomly assigned to receive either a GLP-1 RA (semaglutide) or placebo for 52 weeks [14].